(688217)"Shanghai Rightongene Biotechnology Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688217 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates a significant decline in revenue and net profit compared to the same period last year, reflecting challenges in the industry. The company reported a negative net profit attributable to shareholders, alongside a decrease in research and development investment. The financial statements included in the report have not been audited, and the company assures the accuracy and completeness of the information provided.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Rightongene Biotechnology Co. Ltd. on 6ix
Earlier from Shanghai Rightongene Biotechnology
- (688217)"Shanghai Rightongene Biotechnology Co., Ltd."Announcement on Expiration of Shareholding Reduction Plan of Shareholder Holding More Than 5% of the Shares and Results of Shareholding Reduction
- Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Change in Accounting Policies
- Indicative Announcement on Change in Equity of a Shareholder Holding More Than 5% of the Shares Reaching an Integral Multiple of 5%
Follow Shanghai Rightongene Biotechnology into a list and get an email when it puts out news.
Follow Shanghai Rightongene Biotechnology